MAPK3 and skin neoplasm: Treatment of skin cancer A431 cells by silibinin resulted in cell growth inhibition and death, which was found to be coupled with a decrease in MAPK/ERK1/2 levels and an upregulation of SAPK/JNK1/2 and p38 MAPK activation [136].